Tudor Investment Corp ET AL Sells 202,171 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Tudor Investment Corp ET AL reduced its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 39.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 305,186 shares of the company's stock after selling 202,171 shares during the period. Tudor Investment Corp ET AL owned 0.20% of Xeris Biopharma worth $1,035,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in XERS. NewEdge Advisors LLC acquired a new position in shares of Xeris Biopharma during the 4th quarter worth about $34,000. R Squared Ltd acquired a new position in Xeris Biopharma in the 4th quarter valued at about $42,000. Cibc World Markets Corp purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth approximately $44,000. Raymond James Financial Inc. acquired a new stake in shares of Xeris Biopharma in the 4th quarter worth $45,000. Finally, Aquatic Capital Management LLC purchased a new stake in Xeris Biopharma in the 4th quarter valued at approximately $50,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This represents a 2.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.47% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on XERS shares. Oppenheimer upped their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Craig Hallum boosted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a report on Friday, March 7th. Piper Sandler restated a "neutral" rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Jefferies Financial Group restated a "buy" rating and set a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock traded down $0.15 on Monday, reaching $4.86. 763,274 shares of the company were exchanged, compared to its average volume of 1,931,830. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.77 and a 1-year high of $6.07. The firm has a market cap of $760.19 million, a price-to-earnings ratio of -10.46 and a beta of 1.10. The company's 50-day moving average is $4.66 and its two-hundred day moving average is $3.86.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. As a group, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.